FENC

Fennec Pharmaceuticals Inc. (FENC) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on PEDMARK (sodium thiosulfate injection), the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. The company also holds an exclusive license with Norgine Pharma to commercialize the product (branded as PEDMARQSI) in Europe, Australia, and New Zealand.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Q1 2024 included a one-time licensing revenue of $17.96 million from the Norgine agreement.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 65.5% to $8.75 million. This is primarily due to the absence of the $17.96 million licensing revenue recognized in Q1 2024 from the Norgine agreement. However, net product sales for PEDMARK increased by 18% to $8.75 million, driven by expanded market penetration and focus on the Adolescent and Young Adult (AYA) population.
• Profitability Shift: The company reported a net loss of $1.17 million compared to a net income of $12.84 million in the prior year. The shift is attributable to the non-recurring licensing revenue in 2024 and continued operating expenses.
• Expense Reduction: Selling and marketing expenses decreased by 43% ($2.26 million) due to the completion of European pre-commercial activities following the Norgine licensing deal. General and administrative expenses increased slightly by $0.27 million, largely due to legal costs associated with ongoing patent litigation.
• Debt Reduction: In December 2024, the company redeemed $13.0 million of its senior secured convertible notes. Consequently, interest expense decreased by $0.44 million in Q1 2025.
• Liquidity: Cash and cash equivalents decreased by $3.96 million to $22.68 million, reflecting a net cash outflow from operating activities of $4.32 million.

Outlook, Risks, and Contingencies

• Liquidity Position: Management believes current funds, bolstered by the $43.2 million upfront payment from Norgine, are sufficient to fund operations for at least the next 12 months.
• Patent Litigation: The company is engaged in ongoing patent infringement litigation against CIPLA Ltd. regarding a generic version of PEDMARK. While the company has Orphan Drug Exclusivity until September 2029, CIPLA has filed Paragraph IV certifications alleging patent invalidity. The suit is ongoing, with the company focusing on specific patents (US '018 and US '793) in its Third Amended Complaint.
• Commercialization: Norgine announced the launch of PEDMARQSI in Germany and the U.K. in early 2025. In the U.S., the company continues to expand its sales force and patient access programs.
• Risk Factors: Key risks include the outcome of the CIPLA litigation, the ability to maintain market exclusivity, and the potential impact of tariffs on pharmaceuticals, though management currently does not expect a material impact.

Investor Verification Checklist

• Verify the sustainability of PEDMARK product sales growth ($8.75M in Q1 2025) absent the one-time licensing revenue.
• Monitor the status of the CIPLA patent litigation and the potential impact on the 2029 Orphan Drug Exclusivity protection.
• Assess the burn rate relative to the $22.68 million cash balance and the timeline for achieving cash flow positivity from operations.
• Review the terms of the remaining $19.48 million convertible debt, including the interest rate (Prime + 4.5%) and maturity date (August 2027).
• Confirm the progress of Norgine's commercialization efforts in Europe and the potential for future milestone payments.